糖肾康胶囊对早期糖尿病肾病患者胱抑素C及炎症因子的影响  

Effect of Tangshenkang Capsule on Cystatin C and Inflammatory Factors in Patients with Early Diabetic Nephropathy

作　　者：莫小书 周平 MO Xiaoshu;ZHOU Ping(Department of Endocrinology,Liuyang Hospital of Traditional Chinese Medicine,Hunan Province,Liuyang 410300,China;Department of Spine Surgery,Liuyang Hospital of Traditional Chinese Medicine,Hunan Province,Liuyang 410300,China)

机构地区：[1]浏阳市中医医院内分泌科,湖南浏阳410300 [2]浏阳市中医院脊柱外科,湖南浏阳410300

出　　处：《中国中医药现代远程教育》2020年第13期59-63,共5页Chinese Medicine Modern Distance Education of China

基　　金：湖南省浏阳市中医医院院级科研基金课题【No.LY2017B05】。

摘　　要：目的观察糖肾康胶囊对早期糖尿病肾病患者胱抑素C及炎症因子的作用。方法选取符合纳入标准的180例早期糖尿病肾病患者,按随机数字表法分为治疗组与对照组各90例,2组均予以常规饮食、运动及西药治疗,对照组予以厄贝沙坦片治疗,治疗组予以糖肾康胶囊口服,2组疗程均为3个月;观察2组患者治疗前后临床疗效、中医证候积分、24小时尿蛋白定量(24h-TP)、尿微量白蛋白/肌酐(ACR)、胱抑素C(Cys C)、超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)。结果治疗组总有效率达88.89%,优于对照组的64.44%(P <0.05);治疗组在改善中医证候积分方面优于对照组(P <0.05);治疗组及对照组均能降低患者的BUN、Cr、24h-TP、ACR及Cys C水平(P <0.05),但治疗组效果更好(P <0.05);治疗组在降低患者的炎症因子水平方面优于对照组(P <0.05);治疗组不良反应发生率为3.33%,对照组不良反应发生率为7.78%。结论糖肾康胶囊治疗早期糖尿病肾病临床疗效确切,能够有效降低胱抑素C及炎症因子的水平,抑制机体炎症反应,减少尿微量白蛋白,延缓或逆转糖尿病肾病的进展,值得在临床中推广及进一步研究。Objective To observe the effect of Tangshenkang capsule on cystatin C and inflammatory factors in patients with early diabetic nephropathy. Methods A total of 180 patients with early diabetic nephropathy who met the inclusion criteria were selected and divided into the treatment group and the control group, with 90 patients in each group by random number table method. Both groups were treated with routine diet, exercise and western medicine, while the control group was treated with irbesartan tablets and the treatment group with Tangshenkang capsules. The clinical efficacy, TCM syndrome score, 24-hour urine protein quantitatie(24 h-TP),urinary microalbumin/creatinine(ACR), Cys C, hs-CRP, interleukin 6(IL-6), Tumor necrosis factor(TNF-α) were observed. Results The total effective rate of the treatment group was 88.89%, which was better than that of the control group(64.44%)(P<0.05). The treatment group was superior to the control group in improving TCM syndrome score(P <0.05). Both treatment group and control group could reduce the levels of BUN, Cr, 24 h-TP, ACR and CysC(P<0.05), but the treatment group had better effect(P<0.05). The treatment group was better than the control group in reducing the level of inflammatory factors(P<0.05). The incidence of adverse reactions was 3.33% in the treatment group and 7.78% in the control group. Conclusion Tangshenkang capsule has a definite clinical effect in the treatment of early diabetic nephropathy, which can effectively reduce the level of cystatin C and inflammatory factors,inhibit the inflammatory reaction of the body, reduce microalbumin in urine, and delay or reverse the progression of diabetic nephropathy. It is worth promoting and further studying in clinical practice.

关 键 词：糖肾康胶囊 气阴两虚 夹瘀型 糖尿病肾病 胱抑素C 炎症因子 中成药疗法 消渴 水肿 

分 类 号：R259[医药卫生—中西医结合] R277.5[医药卫生—中医内科学]